Publication | Open Access

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

VaccinationVaccine SafetyVaccine DevelopmentPhase 3ImmunologyPlacebo-controlled TrialVaccine EfficacyImmunotherapyMedicineAs03 AdjuvantCovid-19